Dapagliflozin for eGFR 34 mL/min/1.73 m²
Yes, dapagliflozin is appropriate and recommended at 10 mg once daily for a patient with an eGFR of 34 mL/min/1.73 m², regardless of whether the indication is for glycemic control, cardiovascular protection, or kidney disease progression. 1, 2
Dosing Based on Indication
For Kidney and Cardiovascular Protection (Non-Glycemic Indications)
- Use 10 mg once daily for patients with eGFR ≥25 mL/min/1.73 m² 1, 2
- At eGFR 34, this patient falls well within the approved range for initiation 1
- The KDIGO 2022 and ADA/KDIGO 2022 consensus strongly recommend SGLT2 inhibitors for patients with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m² 1, 3
- Continue dapagliflozin even if eGFR subsequently falls below 25 mL/min/1.73 m² until dialysis or transplantation 1, 2
For Glycemic Control in Type 2 Diabetes
- Dapagliflozin is NOT recommended for glycemic control when eGFR <45 mL/min/1.73 m² 4, 2
- The glucose-lowering efficacy is minimal at this level of kidney function due to the mechanism of action 1
- However, you should still prescribe it at 10 mg daily for cardiovascular and kidney benefits if the patient has type 2 diabetes with CKD 1, 5
Evidence Supporting Use at eGFR 34
The DAPA-CKD trial enrolled patients with eGFR 25-75 mL/min/1.73 m² and demonstrated:
- 39% relative risk reduction in the composite of sustained eGFR decline ≥50%, end-stage kidney disease, or renal/cardiovascular death 6
- Slowed eGFR decline by 0.95 mL/min/1.73 m² per year compared to placebo 7
- Benefits were consistent regardless of type 2 diabetes status 6, 8
- Safety profile remained favorable at lower eGFR levels 6, 9
Practical Implementation
Before Starting Dapagliflozin
- Assess volume status and correct any volume depletion before initiation 1, 10, 2
- Consider reducing thiazide or loop diuretic doses if the patient is at risk for hypovolemia 1, 10
- If the patient is on insulin or sulfonylureas and meeting glycemic targets, consider reducing these doses by approximately 20% for insulin to prevent hypoglycemia 4
Expected eGFR Changes
- Expect an acute eGFR decline of approximately 2-3 mL/min/1.73 m² within the first 2 weeks 7
- This initial dip is hemodynamic, reversible, and not an indication to discontinue therapy 1, 10
- After week 2, dapagliflozin significantly slows the chronic rate of eGFR decline 7
Monitoring
- Monitor eGFR and volume status after drug initiation 1, 10, 2
- Educate patients about symptoms of volume depletion and low blood pressure 1, 10
- Monitor for genital mycotic infections (more common in women) and provide guidance on genital hygiene 1, 11
Common Pitfalls to Avoid
Do not discontinue dapagliflozin due to the initial eGFR dip in the first 2 weeks—this is expected and represents beneficial hemodynamic changes, not kidney injury 1, 10, 7
Do not withhold dapagliflozin solely because eGFR is below 45 mL/min/1.73 m²—while it won't provide glycemic benefit at this level, the kidney and cardiovascular protection remain robust 1, 3
Withhold dapagliflozin during prolonged fasting, major surgery (at least 3 days prior), or critical illness to reduce the risk of euglycemic diabetic ketoacidosis 1, 10, 2
Do not combine with other SGLT2 inhibitors—there is no evidence of additive benefit 12
Special Considerations
For patients ≥65 years of age with eGFR 34, dapagliflozin remains effective and safe, though monitor more closely for hypotension and volume depletion 2
If the patient has type 2 diabetes with higher baseline HbA1c or urinary albumin-to-creatinine ratio, the benefits on eGFR slope preservation are even more pronounced 7, 8
The cardiovascular benefits (reduced heart failure hospitalization and cardiovascular death) are preserved at eGFR 34 regardless of diabetes status 1, 6